Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026

Rapport Therapeutics, Inc.

2026-Q1 EPS reported -$0.42 revenue$20,000,000

Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.
Cash $476.8M at March 31, 2026; runway into 2H 2029.
RAP-219 Phase 3 for focal onset seizures on track to begin Q2 2026; follow-up data showed 90% median seizure reduction weeks 9-12.
Bipolar mania Phase 2 topline results now expected Q4 2026 (ahead of prior 1H 2027 guidance).
R&D expense $32.7M (up from $19.6M); G&A $11.5M ($7.5M); Tenacia collaboration signed March 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rapport Therapeutics, Inc. reported financial results for the quarter ending March 31, 2026.

Period: the quarter ending March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Rapport Therapeutics, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Rapport Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.